Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/124271
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSarink, Danja-
dc.contributor.authorSchock, Helena-
dc.contributor.authorJohnson, Theron-
dc.contributor.authorOvervad, Kim-
dc.contributor.authorHolm, Marianne-
dc.contributor.authorTjønneland, Anne-
dc.contributor.authorBoutron-Ruault, Marie-Christine-
dc.contributor.authorHis, Mathilde-
dc.contributor.authorKvaskoff, Marina-
dc.contributor.authorBoeing, Heiner-
dc.contributor.authorLagiou, Pagona-
dc.contributor.authorPapatesta, Eleni-Maria-
dc.contributor.authorTrichopoulou, Antonia-
dc.contributor.authorPalli, Domenico-
dc.contributor.authorPala, Valeria-
dc.contributor.authorMattiello, Amalia-
dc.contributor.authorTumino, Rosario-
dc.contributor.authorSacerdote, Carlotta-
dc.contributor.authorBueno de Mesquita, H. Bas-
dc.contributor.authorvan Gils, Carla H.-
dc.contributor.authorPeeters, Petra H. M.-
dc.contributor.authorWeiderpass, Elisabete-
dc.contributor.authorAgudo, Antonio-
dc.contributor.authorSanchez, Maria José-
dc.contributor.authorChirlaque, María Dolores-
dc.contributor.authorArdanaz, Eva-
dc.contributor.authorAmiano, Pilar-
dc.contributor.authorKhaw, Kay-Tee-
dc.contributor.authorTravis, Ruth-
dc.contributor.authorDossus, Laure-
dc.contributor.authorGunter, Marc-
dc.contributor.authorRinaldi, Sabina-
dc.contributor.authorMerritt, Melissa-
dc.contributor.authorRiboli, Elio-
dc.contributor.authorKaaks, Rudolf-
dc.contributor.authorFortner, Renée T.-
dc.date.accessioned2018-09-05T06:59:59Z-
dc.date.available2018-09-05T06:59:59Z-
dc.date.issued2017-09-01-
dc.identifier.urihttp://hdl.handle.net/2445/124271-
dc.description.abstractReceptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1,976 incident invasive breast cancer cases [estrogen receptor positive (ER+), n = 1,598], matched 1: 1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (P-het = 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63); P-trend = 0.20], but not ER+ disease. For both ER+ and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER+PR+ disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14); P-trend = 0.03]. This study provides the first large-scale prospective data on circulating sRANKL and breast cancer. We observed limited evidence for an association between sRANKL and breast cancer risk.-
dc.format.extent20 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherAmerican Association for Cancer Research-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1158/1940-6207.CAPR-17-0125-
dc.relation.ispartofCancer Prevention Research, 2017, vol. 10, num. 9, p. 525-534-
dc.relation.urihttps://doi.org/10.1158/1940-6207.CAPR-17-0125-
dc.rights(c) American Association for Cancer Research, 2017-
dc.subject.classificationCàncer de mama-
dc.subject.classificationReceptors d'hormones-
dc.subject.otherBreast cancer-
dc.subject.otherHormone receptors-
dc.titleCirculating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.date.updated2018-07-24T12:01:38Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
SarinkD.pdf356.98 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.